Luc Marengere

Marengere oversees the establishment of the new Canadian operations and the North American investment strategy as well as deal sourcing and execution. Marengere joins TVM Capital after more than 15 years of venture capital experience in Canada and the U.S. Most recently, Marengere was a Managing General Partner with VG Partners where he successfully launched and oversaw the operations and investments of the VG Advanced Life Sciences Fund (VG ALSF). Luc was a Director on the Boards of Trillium Technologies Inc., (Toronto, ON); Cytochroma Inc., (Toronto, ON); Aegera Therapeutics, Inc. (Montréal, QC); Cita Neuropharma (sold to Vernalis Plc, UK), (Toronto, ON) and lastly Argos Therapeutics Inc., (Durham, NC). Luc also invested in VisualSonics, Inc. (sold to U.S.-based SonoSite), (Toronto, ON). Prior to joining VG Partners, he focused on making venture investments in the life science sector while with CDP Capital – Technology Ventures and MDS Capital Corp. Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. He holds a Ph.D. from University of Toronto’s department of Medical Biophysics and Molecular Genetics.